Deaf-Blind Disorders

22  relevant articles (0 outcomes, 0 trials/studies) found for this Disease

Blindness-Deafness; Deaf-Blind Syndromes; Deaf-Blindness Disorders; Deaf-Mutism-Blind Disorders; Deafness-Blindness; Hearing and Vision Loss; Prelingual Deaf-Blind Disorders; Prelingual Deafness-Blindness; Vision and Hearing Loss; Blind Deaf Disorders; Blind-Deaf Disorder; Blindness Deafness; Deaf Blind Disorders; Deaf Blind Syndromes; Deaf Blindness Disorders; Deaf Mutism Blind Disorders; Deaf-Blind Disorder; Deaf-Blind Disorder, Prelingual; Deaf-Blind Disorders, Prelingual; Deaf-Blind Syndrome; Deaf-Blindness Disorder; Deaf-Mutism-Blind Disorder; Deafness Blindness; Deafness-Blindness, Prelingual; Deafness-Blindnesses, Prelingual; Disorder, Blind-Deaf; Disorder, Deaf-Blind; Disorder, Deaf-Blindness; Disorder, Deaf-Mutism-Blind; Disorder, Prelingual Deaf-Blind; Disorders, Blind-Deaf; Disorders, Deaf-Blind; Disorders, Deaf-Blindness; Disorders, Deaf-Mutism-Blind; Disorders, Prelingual Deaf-Blind; Prelingual Deaf Blind Disorders; Prelingual Deaf-Blind Disorder; Prelingual Deafness Blindness; Prelingual Deafness-Blindnesses; Syndrome, Deaf-Blind; Syndromes, Deaf-Blind; Blind-Deaf Disorders

Disease Context: Research Results

Related Diseases

1.	Usher Syndromes (Usher Syndrome)
2.	Retinopathy of Prematurity (Retrolental Fibroplasia)
3.	Infection
4.	Hemorrhage
5.	Cerebral Palsy (Spastic Diplegia)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Deaf-Blind Disorders:

1.	ROPIBA 01/01/2005 - "Infants were divided into 3 groups: (A) normal development (n = 35; 48%), (B) mild-to-moderate impairment (IQ 68-83, or mild to moderate hearing loss or visual problems, or mild/moderate CP or ADHD) (n = 25; 36%) and (C) severe impairment (IQ < 68, deafness, blindness or severe CP) (n = 13; 18%) RESULTS: The studied groups differ in respect to: gestational age (mean +/- SEM: 29.7 +/- 2.3 vs 28.1 +/- 2.5 vs 28.5 +/- 2.3 wks; p = 0.03), prevalence of retinopathy (ROP) (17 vs 28 vs 69%; p < 0.01), bronchopulmonary dysplasia (BPD) (31 vs 17 vs 62%; p = 0.03) and periventricular leukomalacia (PVL) (3 vs 0 vs 23%; p < 0.02). " 01/01/2009 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including need for home oxygen, or need for late rescue with corticosteroids), death or CLD, failure to extubate, complications in the primary hospitalisation (including infection, hyperglycaemia, glycosuria, hypertension, echodensities on ultrasound scan of brain, necrotising enterocolitis (NEC), gastrointestinal (GI) bleeding, GI perforation, intraventricular hemorrhage (IVH), severe retinopathy of prematurity (ROP), and long-term outcomes (including blindness, deafness, cerebral palsy and major neurosensory disability), were abstracted and analysed using RevMan 5 MAIN RESULTS: Nineteen RCTs enrolling a total of 1345 participants were eligible for this review. " 01/01/2003 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including need for home oxygen, or need for late rescue with corticosteroids), death or CLD, failure to extubate, complications in the primary hospitalisation (including infection, hyperglycaemia, glycosuria, hypertension, echodensities on ultrasound scan of brain, necrotising enterocolitis (NEC), gastrointestinal bleeding, intestinal perforation, and severe retinopathy of prematurity (ROP)), and long term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability), were abstracted and analysed using RevMan 4.1. " 01/01/2003 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including late rescue with corticosteroids, or need for home oxygen therapy), death or CLD, failure to extubate, complications during the primary hospitalisation (including infection, hyperglycaemia, hypertension, hypertrophic cardiomyopathy, pneumothorax, severe intraventricular haemorrhage (IVH), necrotizing enterocolitis (NEC), gastrointestinal bleeding, and severe retinopathy of prematurity (ROP)), and long term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability), were abstracted and analysed using RevMan 4.1. " 01/01/2009 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including late rescue with corticosteroids, and need for home oxygen therapy), death or CLD, failure to extubate, complications during the primary hospitalisation (including infection, hyperglycaemia, hypertension, pulmonary air leak, patent ductus arteriosus (PDA), severe intraventricular haemorrhage (IVH), periventricular leucomalacia (PVL), necrotising enterocolitis (NEC), gastrointestinal bleeding, intestinal perforation, severe retinopathy of prematurity (ROP), and long-term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability) were abstracted and analysed using RevMan 5. MAIN RESULTS: Twenty-eight RCTs enrolling a total of 3740 participants were eligible for inclusion in this review. " Order ALL the reference details at left...
2.	OxygenIBA 01/01/2009 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including need for home oxygen, or need for late rescue with corticosteroids), death or CLD, failure to extubate, complications in the primary hospitalisation (including infection, hyperglycaemia, glycosuria, hypertension, echodensities on ultrasound scan of brain, necrotising enterocolitis (NEC), gastrointestinal (GI) bleeding, GI perforation, intraventricular hemorrhage (IVH), severe retinopathy of prematurity (ROP), and long-term outcomes (including blindness, deafness, cerebral palsy and major neurosensory disability), were abstracted and analysed using RevMan 5 MAIN RESULTS: Nineteen RCTs enrolling a total of 1345 participants were eligible for this review. " 01/01/2003 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including need for home oxygen, or need for late rescue with corticosteroids), death or CLD, failure to extubate, complications in the primary hospitalisation (including infection, hyperglycaemia, glycosuria, hypertension, echodensities on ultrasound scan of brain, necrotising enterocolitis (NEC), gastrointestinal bleeding, intestinal perforation, and severe retinopathy of prematurity (ROP)), and long term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability), were abstracted and analysed using RevMan 4.1. " 01/01/2003 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including late rescue with corticosteroids, or need for home oxygen therapy), death or CLD, failure to extubate, complications during the primary hospitalisation (including infection, hyperglycaemia, hypertension, hypertrophic cardiomyopathy, pneumothorax, severe intraventricular haemorrhage (IVH), necrotizing enterocolitis (NEC), gastrointestinal bleeding, and severe retinopathy of prematurity (ROP)), and long term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability), were abstracted and analysed using RevMan 4.1. " 01/01/2009 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including late rescue with corticosteroids, and need for home oxygen therapy), death or CLD, failure to extubate, complications during the primary hospitalisation (including infection, hyperglycaemia, hypertension, pulmonary air leak, patent ductus arteriosus (PDA), severe intraventricular haemorrhage (IVH), periventricular leucomalacia (PVL), necrotising enterocolitis (NEC), gastrointestinal bleeding, intestinal perforation, severe retinopathy of prematurity (ROP), and long-term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability) were abstracted and analysed using RevMan 5. MAIN RESULTS: Twenty-eight RCTs enrolling a total of 3740 participants were eligible for inclusion in this review. " 01/01/2003 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including late rescue with corticosteroids, and need for home oxygen therapy), death or CLD, failure to extubate, complications during the primary hospitalisation (including infection, hyperglycaemia, hypertension, pulmonary air leak, patent ductus arteriosus (PDA), severe intraventricular haemorrhage (IVH), periventricular leucomalacia (PVL), necrotising enterocolitis (NEC), gastrointestinal bleeding, intestinal perforation, severe retinopathy of prematurity (ROP), and long-term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability) were abstracted and analysed using RevMan 4.1. " Order ALL the reference details at left...
3.	Adrenal Cortex Hormones (Corticosteroids)IBA 01/01/2009 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including need for home oxygen, or need for late rescue with corticosteroids), death or CLD, failure to extubate, complications in the primary hospitalisation (including infection, hyperglycaemia, glycosuria, hypertension, echodensities on ultrasound scan of brain, necrotising enterocolitis (NEC), gastrointestinal (GI) bleeding, GI perforation, intraventricular hemorrhage (IVH), severe retinopathy of prematurity (ROP), and long-term outcomes (including blindness, deafness, cerebral palsy and major neurosensory disability), were abstracted and analysed using RevMan 5 MAIN RESULTS: Nineteen RCTs enrolling a total of 1345 participants were eligible for this review. " 01/01/2003 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including need for home oxygen, or need for late rescue with corticosteroids), death or CLD, failure to extubate, complications in the primary hospitalisation (including infection, hyperglycaemia, glycosuria, hypertension, echodensities on ultrasound scan of brain, necrotising enterocolitis (NEC), gastrointestinal bleeding, intestinal perforation, and severe retinopathy of prematurity (ROP)), and long term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability), were abstracted and analysed using RevMan 4.1. " 01/01/2003 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including late rescue with corticosteroids, or need for home oxygen therapy), death or CLD, failure to extubate, complications during the primary hospitalisation (including infection, hyperglycaemia, hypertension, hypertrophic cardiomyopathy, pneumothorax, severe intraventricular haemorrhage (IVH), necrotizing enterocolitis (NEC), gastrointestinal bleeding, and severe retinopathy of prematurity (ROP)), and long term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability), were abstracted and analysed using RevMan 4.1. " 01/01/2009 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including late rescue with corticosteroids, and need for home oxygen therapy), death or CLD, failure to extubate, complications during the primary hospitalisation (including infection, hyperglycaemia, hypertension, pulmonary air leak, patent ductus arteriosus (PDA), severe intraventricular haemorrhage (IVH), periventricular leucomalacia (PVL), necrotising enterocolitis (NEC), gastrointestinal bleeding, intestinal perforation, severe retinopathy of prematurity (ROP), and long-term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability) were abstracted and analysed using RevMan 5. MAIN RESULTS: Twenty-eight RCTs enrolling a total of 3740 participants were eligible for inclusion in this review. " 01/01/2003 - "DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including late rescue with corticosteroids, and need for home oxygen therapy), death or CLD, failure to extubate, complications during the primary hospitalisation (including infection, hyperglycaemia, hypertension, pulmonary air leak, patent ductus arteriosus (PDA), severe intraventricular haemorrhage (IVH), periventricular leucomalacia (PVL), necrotising enterocolitis (NEC), gastrointestinal bleeding, intestinal perforation, severe retinopathy of prematurity (ROP), and long-term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability) were abstracted and analysed using RevMan 4.1. " Order ALL the reference details at left...
4.	myosin VIIaIBA 08/01/2005 - "Defects in myosin VIIa, the PDZ-domain-containing protein harmonin, cadherin 23, protocadherin 15, and the putative scaffolding protein sans, underlie five genetic forms of Usher syndrome type I (USH1), the most frequent cause of hereditary deafness-blindness in humans. " 05/27/2003 - "Mutations in the myosin VIIa gene (MYO7A) cause Usher syndrome type 1B (USH1B), a major type of the deaf-blind disorder, Usher syndrome. " 08/01/1999 - "Two types of Usher syndrome, a blindness-deafness disorder, result from mutations in the myosin VIIa gene. " 10/15/2005 - "Defects in myosin VIIa, the PDZ-domain-containing protein harmonin, cadherin 23 and protocadherin 15 (two cadherins with large extracellular regions), and the putative scaffolding protein Sans underlie five genetic forms of Usher syndrome type I (USH1), the most frequent cause of hereditary deafness-blindness in humans. " 01/01/1997 - "Recently, mutations in the gene for an unconventional myosin, myosin-VIIa, were found to be the basis for the deafness and vestibular dysfunction observed in shaker-1 (sh1) mice and for a human deafness-blindness syndrome, Usher syndrome type 1B. " Order ALL the reference details at left...
5.	Retinaldehyde (Retinal)IBA 09/01/1996 - "Blindness, deafness, quadriparesis, and a retinal malformation: the ravages of neurofibromatosis 2." 07/01/1995 - "Also the syndrome with encephalopathy, deafness, blindness and ataxia in young women is attributed to microangiopathy with small brain infarcts and retinal infarcts. " Order ALL the reference details at left...
6.	Olfactory Marker ProteinIBA 01/01/1994 - "The mouse olfactory marker protein gene (Omp) maps close to the deafness mutation shaker-1 (sh-1) and has been considered a candidate gene for both sh-1 and its potential human homolog, the deaf-blind syndrome Usher Type I. Using primers devised from the available rat Olfactory Marker Protein gene sequence, we have determined the coding sequence of the mouse gene in both control inbred strains and six shaker-1 mutants. " Order ALL the reference details at left...
7.	Cadherins (E-Cadherin)IBA 10/15/2005 - "Defects in myosin VIIa, the PDZ-domain-containing protein harmonin, cadherin 23 and protocadherin 15 (two cadherins with large extracellular regions), and the putative scaffolding protein Sans underlie five genetic forms of Usher syndrome type I (USH1), the most frequent cause of hereditary deafness-blindness in humans. " Order ALL the reference details at left...
8.	Myosins (Myosin)IBA 01/01/1997 - "Recently, mutations in the gene for an unconventional myosin, myosin-VIIa, were found to be the basis for the deafness and vestibular dysfunction observed in shaker-1 (sh1) mice and for a human deafness-blindness syndrome, Usher syndrome type 1B. " Order ALL the reference details at left...
9.	IronIBA 04/01/1990 - "The use of deferoxamine for iron chelation in transfusion-dependent thalassemia major is limited by serious neurotoxicity (hearing and vision loss). " Order ALL the reference details at left...
10.	Mitochondrial DNA (mtDNA)IBA 06/15/2007 - "However, the incomplete penetrance of vision and hearing loss suggests the involvement of nuclear modifier genes and environmental factors in the phenotypic expression of these mtDNA mutations." Order ALL the reference details at left...

Therapies and Procedures

1.	Prostheses and Implants (Prosthesis) 12/01/2005 - "Sensory cortical prostheses have potential to aid people suffering from blindness, deafness and other sensory deficits. " 03/01/1977 - "Other rubella consequences such as blindness, deafness, and cardiac and neuromuscular defects remained present except as modified by operations and prostheses. " Order ALL the reference details at left...
2.	Activities of Daily Living (ADL) 05/01/1999 - "This paper examines the moderating effects of three psychological attributes (neuroticism, self-efficacy expectancies and mastery) on the association between functional limitations (motor and cognitive limitation, vision and hearing loss) and disability ((instrumental) activities of daily living, role function and social function) in a sample of 624 community-dwelling older persons. " 09/01/1998 - "INTRODUCTION: we have tested the hypothesis that the co-occurrence of common impairments (motor and cognitive impairments, vision and hearing loss, depressive symptoms) of later life have exacerbating effects on disability [activities and instrumental activities of daily living, social and role function, (in)activity]. " Order ALL the reference details at left...